Iron they’ll actually take1
ACCRUFeR®(ferric maltol) has a unique "maltol shield" that protects the iron as it passes through the stomach, resulting in unprecedented GI tolerability and clinically proven efficacy.2,3
ACCRUFeR® (ferric maltol) is an FDA approved oral iron treatment for adults with iron deficiency.2
See what sets ACCRUFeR apart.
-
Unprecedented tolerability
In clinical studies, 4.6% of patients taking ACCRUFeR (n=175) discontinued treatment due to adverse gastrointestinal reactions, compared with 2.5% of patients taking a placebo (n=120).2,5,6See the studies -
Unique "maltol shield"
ACCRUFeR is a non-salt ferric iron uniquely formulated with a "maltol shield" that keeps iron intact as it passes through the stomach. This reduces the likelihood of reactive oxygen species (ROS) formation, which in turn minimizes GI side effects.3,4See for yourself -
Established safety and efficacy
Dig deeperACCRUFeR achieved FDA approval based on three pivotal studies in patients with ID/IDA associated with chronic inflammation and malabsorption.*,1,5 Among patients taking ACCRUFeR, significant improvements were seen across iron indices, including hemoglobin, ferritin, and TSAT.5,6
*Avoid use in patients with IBD flare.2
-
Available at the lowest price possible
We’re committed to making ACCRUFeR accessible for your patients. Eligible patients may pay as little as $0 for ACCRUFeR.Help your patients
References:
1. Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44(3):259-270. doi:10.1111/apt.13665
2. ACCRUFeR® full prescribing information. Shield Therapeutics, 2023.
3. Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16(18):2859-2867. doi:10.1517/14656566.2015.1096929
4. European Medicines Agency. Accessed March 17, 2021. https://www.ema.europa.eu/en/documents/variation-report/feraccru-h-c-2733-ii-0010-epar-assessment-report-variation_en.pdf.
5. Gasche C, Ahmad T, Zsolt T, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579-588.
6. Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021;78(6):846- 856.e1. doi:10.1053/j.ajkd.2021.03.020
7. Data on file. Shield Therapeutics Inc. 2019.
1. Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44(3):259-270. doi:10.1111/apt.13665
2. ACCRUFeR® full prescribing information. Shield Therapeutics, 2023.
3. Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16(18):2859-2867. doi:10.1517/14656566.2015.1096929
4. European Medicines Agency. Accessed March 17, 2021. https://www.ema.europa.eu/en/documents/variation-report/feraccru-h-c-2733-ii-0010-epar-assessment-report-variation_en.pdf.
5. Gasche C, Ahmad T, Zsolt T, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579-588.
6. Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021;78(6):846- 856.e1. doi:10.1053/j.ajkd.2021.03.020
7. Data on file. Shield Therapeutics Inc. 2019.
